"Dutasteride" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A 5-ALPHA-REDUCTASE INHIBITOR that is reported to inhibit both type-1 and type2 isoforms of the enzyme and is used to treat BENIGN PROSTATIC HYPERPLASIA.
| Descriptor ID |
D000068538
|
| MeSH Number(s) |
D04.210.500.925.100.125
|
| Concept/Terms |
Dutasteride- Dutasteride
- 17beta-N-(2,5-bis(trifluoromethyl))phenyl-carbamoyl-4-aza-5alpha-androst-1-en-3-one
|
Below are MeSH descriptors whose meaning is more general than "Dutasteride".
Below are MeSH descriptors whose meaning is more specific than "Dutasteride".
This graph shows the total number of publications written about "Dutasteride" by people in this website by year, and whether "Dutasteride" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 1 | 2 | 3 |
| 2018 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Dutasteride" by people in Profiles.
-
This Month in JAAD: May 2021. J Am Acad Dermatol. 2021 05; 84(5):1249.
-
Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men. J Eur Acad Dermatol Venereol. 2021 Jan; 35(1):e13-e15.
-
A population-based study of the risk of osteoporosis and fracture with dutasteride and finasteride. BMC Musculoskelet Disord. 2018 May 22; 19(1):160.
-
Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men - short version. J Eur Acad Dermatol Venereol. 2018 Jan; 32(1):11-22.
-
Frontal fibrosing alopecia: clinical and prognostic classification. J Eur Acad Dermatol Venereol. 2017 Oct; 31(10):1739-1745.
-
Dutasteride add-on therapy reduces detrusor mass in patients with benign prostatic enlargement not satisfied with alpha-adrenergic antagonist monotherapy: A single center prospective study. Neurourol Urodyn. 2017 Nov; 36(8):2096-2100.